QIAGEN NV Stock News

REDWOOD CITY, Calif. & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. Leveraging AI technology, IPA Interpret helps distill complex differential expression analyses into actionable ...

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has reached a significant milestone with over 1,000 placements of the EZ2 Connect automated sample preparation instrument, an advancement of the EZ1 instrument line. Launched in 2021, the updated EZ2 Connect has quickly become a market-leading instrument for sample prepar...

BARCELONA, Spain & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business. Set to open in early 2026, the new site will cover the entire value chain for the QIAstat-Dx system,...

QIAGEN introduces market's first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custom Assay Design Tool for Microbial dPCR Assays offers unparalleled flexibility in digital PCR analysis of bacterial, fungal and viral targets // QIAseq xHYB Custom Microbial Panels enable high-resol...

Qiagen N.V. (NYSE:QGEN ) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ET Company Participants John Gilardi - VP, Head of Corporate Communications and IR Thierry Bernard - CEO Roland Sackers - CFO Conference Call Participants Patrick Donnelly - Citi Odysseas Manesiotis - Berenberg Matt Sykes - Goldman Sachs Doug Schenkel - Wolfe Research Aisyah Noor - Morgan Stanley Michael Ryskin -...

Qiagen reported a rise in third-quarter revenue on Wednesday, owing to strong sales of its diagnostic devices.

Der Labordienstleister Qiagen NL0012169213 hat im vergangenen Quartal von einer anziehenden Nachfrage nach Diagnostiklösungen profitiert und seinen Umsatz überraschend stark gesteigert.

QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat‑Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections –...